Perspectives
Biologics dominate treatment costs for Crohn’s and ulcerative colitis
BIologic drug therapy makes up more than 70% of the total cost of care for either condition
October 19, 2019Biologic therapy makes up more than 70% of the total cost of care for members with either Crohn’s disease (CD) or ulcerative colitis (UC)
Crohn’s disease and ulcerative colitis are the two major types of inflammatory bowel disease (IBD). This study determined that biologic therapy makes up most of the annual total pharmacy and medical costs. It shows real-world prevalence, utilization, and total health care costs to improve understanding of the conditions. It adds Prime’s insights to the industry dialogue tying drug cost to value. But it’s clear that it is not possible to obtain a direct medical care cost offset to biologic therapy in IBD.
Related news
Perspectives
August 4, 2022
Specialty Pipeline Update: July 2022
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…
Perspectives
August 4, 2022
Traditional Drug Pipeline Update: July 2022
This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…
Perspectives
July 26, 2022
Working together to lead the way
We often have the impression that advancing and leading in your career requires…